
EARS
Healthcare · Biotechnology · $39.2M market cap
Latest report
Time not confirmed
The next earnings date isn’t on the calendar yet.
Analyst consensus
Fiscal period ending Dec 31, 2020
EPS trend, 90 days to now · +100.0% over 90 days · 30-day revisions 0 up, 0 down
Beat estimates in 0 of the last 4 reported quarters.
EPS surprise versus the estimate at the time of the report.
| Date | Session | Estimate | Actual | Surprise |
|---|---|---|---|---|
| Dec 31, 2020 | Time not confirmed | 0.00 | -0.42 | — |
| Sep 30, 2020 | Time not confirmed | 0.00 | -0.40 | — |
| Jun 30, 2020 | Time not confirmed | 0.00 | -0.31 | — |
| Mar 31, 2020 | Time not confirmed | 0.00 | -0.30 | — |
| Dec 31, 2019 | Time not confirmed | 0.00 | -0.43 | — |
| Sep 30, 2019 | Time not confirmed | -1.60 | -0.42 | +74.0% |
| Jun 30, 2019 | Time not confirmed | 0.00 | -0.85 | — |
| Mar 14, 2019 | After the close | -2.22 | -0.62 | +72.0% |
| Nov 15, 2018 | After the close | -2.22 | -2.83 | -27.6% |
| Aug 15, 2018 | Time not confirmed | -32.79 | -10.21 | +68.8% |
| May 15, 2018 | Time not confirmed | — | -6.41 | — |
| Mar 22, 2018 | Time not confirmed | — | -20.26 | — |
Auris Medical Holding Ltd., a clinical-stage biopharmaceutical company, developing therapeutics that address important unmet medical needs in neurotology, rhinology and allergy, and CNS disorders. The company's Phase 3 programs under the development include Keyzilen (AM-101) for the treatment of acute inner ear tinnitus; and Sonsuvi (AM-111) for the treatment of acute inner ear hearing loss. It is also developing…